Loading...
Docoh

Merus (MRUS)

Utility
Antibodies that bind EGFR and ErbB3
23 Nov 20
The invention relates in one aspect to bispecific antibodies comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds Erb B-3, wherein the antibody has a half maximal growth inhibitory concentration (IC50) of less than 200 pM for inhibiting EGFR and/or Erb B-3 ligand induced growth of Bx PC3 cells or Bx PC3-luc2 cells.
Ton Logtenberg, Mark Throsby, Robertus Cornelis Roovers
Filed: 26 Feb 15
Utility
Binding Molecules That Modulate a Biological Activity Expressed by a Cell
14 Oct 20
The invention provides means and methods for inhibiting a biological activity of cells.
Cecilia Anna Wilhelmina GEUIJEN, Rinse KLOOSTER, Cornelis Adriaan DE KRUIF, Paulus Johannes TACKEN, Mark THROSBY, Ton LOGTENBERG
Filed: 5 Jul 18
Utility
Antibody Producing Non-human Animals
7 Oct 20
Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is a common human, human-like, or humanized light chain.
Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. De Kruif, Erwin Houtzager
Filed: 18 Jun 20
Utility
Antibodies for the Treatment of ERBB-2/ERBB-3 Positive Tumors
16 Sep 20
The invention relates to the field of antibodies.
Mark THROSBY, Cecillia Anna Wilhelmina GEUIJEN, David Andre Baptiste MAUSSANG-DETAILLE, Ton LOGTENBERG
Filed: 2 Apr 18
Utility
Methods and means for the production of ig-like molecules
24 Aug 20
The invention provides means and methods for producing one or more Ig-like molecules in a single host cell.
Cornelis Adriaan De Kruif, Linda Johanna Aleida Hendriks, Ton Logtenberg
Filed: 19 May 19
Utility
Antibodies That Bind Egfr and Cmet
5 Aug 20
The invention as disclosed herein relates to bispecific antibodies that comprises a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET).
Cecilia Anna Wilhelmina GEUIJEN, Robertus Cornelis ROOVERS, Mark THROSBY, Cornelis Adriaan De Kruif, Ton Logtenberg
Filed: 8 Aug 18
Utility
Generation of Binding Molecules
5 Aug 20
Provided are methods for efficiently and comprehensively screening antibody repertoires from B cells to obtain and produce molecules with binding characteristics and functional activities for use in human therapy.
Mark THROSBY, Ton LOGTENBERG, John DE KRUIF
Filed: 16 Apr 20
Utility
Bispecific Anti PD1-ANTI TIM3 Antibodies
8 Jul 20
The disclosure provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) mediated inhibition in a PD-1 and/or TIM-3 positive cell.
Cecilia Anna Wilhelmina GEUIJEN, Rinse KLOOSTER, Cornelis Adriaan DE KRUIF, Paulus Johannes TACKEN, Mark THROSBY, Ton LOGTENBERG
Filed: 5 Jul 18
Utility
Antibodies That Modulate a Biological Activity Expressed by a Cell
8 Jul 20
The invention provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and Lymphocyte activation 3 (LAG 3) mediated inhibition in a PD-1 and/or LAG3 positive cell.
Cecilia Anna Wilhelmina GEUIJEN, Rinse KLOOSTER, Cornelis Adriaan DE KRUIF, Paulus Johannes TACKEN, Mark THROSBY, Ton LOGTENBERG
Filed: 5 Jul 18
Utility
Method for selecting a single cell expressing a heterogeneous combination of antibodies
1 Jun 20
The present invention provides combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other.
Hendricus Renerus Jacobus Mattheus Hoogenboom, Ton Logtenberg
Filed: 20 Aug 17
Utility
Generation of binding molecules
11 May 20
Provided are methods for efficiently and comprehensively screening antibody repertoires from B cells to obtain and produce molecules with binding characteristics and functional activities for use in human therapy.
Mark Throsby, Ton Logtenberg, John De Kruif
Filed: 21 Nov 17
Utility
ERBB-2 and ERBB3 Binding Bispecific Antibodies for Use In the Treatment of Cells That Have an NRG1 Fusion Gene
1 Apr 20
The invention relates to the field of antibodies.
Mark THROSBY, Cecilia Anna Wilhelmina GEUIJEN, David Andre Baptiste MAUSSANG-DETAILLE, Ton LOGTENBERG
Filed: 2 Apr 18
Utility
Antibody producing non-human animals
30 Mar 20
Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is a common human, human-like, or humanized light chain.
Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. Dekruif, Erwin Houtzager
Filed: 26 Apr 16
Utility
Binding Molecules That Modulate a Biological Activity Expressed by a Cell
15 Jan 20
The invention provides means and methods of stimulating activity of a member of the TNF receptor superfamily on a cell.
Cecilia Anna Wilhelmina GEUIJEN, Mark THROSBY, Cornelis Adriaan DE KRUIF, Rinse KLOOSTER, Paulus Johannes TACKEN, Ton LOGTENBERG
Filed: 21 Sep 17
Utility
Methods and Means for the Production of Ig-like Molecules
15 Jan 20
The invention provides means and methods for producing one or more Ig-like molecules in a single host cell.
Cornelis Adriaan DE KRUIF, Linda Johanna Aleida Hendriks, Ton Logtenberg
Filed: 19 May 19
Reissue
Recombinant production of mixtures of antibodies
16 Dec 19
Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell.
Patricius H. C. Van Berkel, Ronald Hendrik Brus, Ton Logtenberg, Abraham Bout
Filed: 17 May 16
Utility
Bispecific Igg Antibodies As T Cell Engagers
20 Nov 19
Bispecific IgG antibodies which bind to CLEC12A and an antigen on an immune effector cell are provided.
Alexander Berthold Hendrik Bakker, Pieter Fokko Van Loo, Ton Logtenberg
Filed: 18 Apr 19
Utility
Multivalent Antibody
20 Nov 19
The invention relates to a multivalent antibody which comprises: a base antibody portion which comprises two binding domains; and at least one additional binding domain, wherein the base antibody portion is connected by a linker to the at least one additional binding domain, wherein each binding domain of the base antibody portion and each of the at least one additional binding domains all have a common variable region, and wherein the linker comprises a hinge sequence or a sequence derived from a hinge sequence.
Cornelis Adriaan de Kruif, Linda Johanna Aleida Hendriks, Ton Logtenberg
Filed: 28 Mar 19
  • 1
Patents are sorted by USPTO publication date, most recent first